Relevium Technologies

publicPublic Group

Relevium is a publicly traded corporation strategically focused the acquisition of e-retail brands, products and technologies in the health and wellness market. Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Our s...

people9 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
Add Corporate Feed


Relevium Technologies

publicPublicGroup

Relevium is a publicly traded corporation strategically focused the acquisition of e-retail brands, products and tech......

people9 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

3 hours ago

8020 Admin posted a press release Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company in RELEVIUM TECHNOLOGIES

Provides Futher Information on Newscope Transaction


MONTREAL, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract manufacturing company through its wholly owned subsidiary BGX e-Health LLC. The transaction is subject to customary due diligence and the parties have agreed to keep the vendors information confidential until such a time when the definitive agreement is executed. 


The target of the transaction is a Montreal based Biopharma company that manufactures for private label, white label and for its own brands of over the counter health products sold in Canada and the US.


The acquisition of the target represents a strategic vertical integration for BGX E-Health, and it is forecasted to have a material impact on the subsidiary’s revenues and a significant increase in gross margins, while providing at the same time immediate access to lucrative news opportunities. The addition of the target will also allow the company to pursue private label solutions in North America and its laboratories will enable the company to conduct research and development for new products.


Proposed terms of the LOI


Subject to customary due diligence, board and TSX Venture approval, the Company intends to close the transaction within 90 days from the date of the definitive agreement. An initial payment of 150,000$ in shares and 100,000$ in cash will be done at closing, with an earnout (the “Earnout”) bonus of $2,500,000 in shares vesting over a period of three reference years (20/30/50) and based on specific revenue and EBITDA targets. The final terms and conditions of the transaction will be outlined at the execution of a definitive agreement. The preliminary terms of the earnout include:



  • First Year: Vendor will be entitled to 20% or $500,000 upon meting the forecasted targets for revenue and EBITDA for the first reference 12-month period.

  • Second Year: Vendor will be entitled to 30% or $750,000 upon meeting the forecasted targets for revenue and EBITDA for the second reference 12-month period.

  • Third Year: Vendor will be entitled to 50% or $1,250,000 upon meeting the forecasted targets for revenue and EBITDA for the third reference 12-month period.


Aurelio Useche, CEO of Relevium Technologies stated: “The proposed acquisition is not only of strategic importance to BGX, but also it is accretive in terms of vertical integration, revenue growth, gross margins and EBITDA. The proposed acquisition is expected to consolidate the manufacturing of all-natural products of future brand acquisitions, thus establishing in Montreal an important manufacturing foothold.”   


INFORMATION UPDATE ON NEWS RELEASE REGARDING LOI WITH NEWSCOPE


On October 29, 2019 the Company disseminated a news release announcing it had received a letter of intent (the “LOI”) to roll its interest in wholly owned subsidiary BGX e-Health LLC into Newscope Capital Corporation (“Newscope”).


Newscope Capital Corporation is an arms’ length company incorporated under the laws of British Columbia and it is seeking to become an aggregator in the wellness space, including CBD and hemp. The bona fide letter of intent to acquire BGX E-Health LLC, represents the first major transaction for Newscope, which is expected to complete its listing on the CSE during the first quarter of 2020.


As described in the news release dated October 29, 2019, the preliminary terms of the LOI require Relevium Technologies to roll its interest in BGX E-Health LLC into Newscope (the “RTO”) for a total estimated transaction value $10 million, a transaction that is subject to the completion mutual due diligence. Newscope will issue an initial deposit of $500,000 in cash upon completion of the due diligence period and execution of a binding agreement. The total proposed transaction includes the business, its assets and liabilities, intellectual property and certain key agreements currently under consideration and review by management. The arm’s length offer has not been validated by an independent valuation contractor.


The foregoing transactions are subject to regulatory approvals. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


About Relevium Technologies
Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

1 day ago

8020 Admin posted a press release Relevium Technologies Appoints Mark Billings as Chief Financial Officer in RELEVIUM TECHNOLOGIES


MONTREAL, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and Biocannabix Health Corporation effective immediately. Mr. Billings replaces Faycal Salek who has resigned to pursue other opportunities.


Mr. Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business. Mr. Billings has founded and managed companies in the junior resource sector, where he acted as CEO, CFO and board member. Mr. Billings serves on the board of several publicly traded resource companies in Canada and abroad. In addition to his executive career, Mr. Billings has been an investment banker, having raised hundreds of millions of dollars for small-cap companies, including several junior mining companies. 


Aurelio Useche, CEO of  Relevium stated: “Mr. Billings is a veteran in the public markets and brings to our company extensive experience in capital markets, M&A transactions and overall financial acumen, all of which are necessary for the next stage of the development of our business. We look forward to his active participation in the strategic planning process, development and execution of the company’s objectives


Mr. Useche continued: “On behalf of the entire board and management team, we would like to thank Mr. Faycal Salek for his valuable contributions and wish him success in his new endeavors.


About Relevium Technologies
Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The Company has an international ecosystem and footprint that ensures vertical integration from phyto-genetics through clinical validation and eventual commercialization of its products.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

9 days ago

8020 Admin posted a press release Relevium's Subsidiary BGX E-Health Secures One Million Dollar Export Contract for the Middle East in RELEVIUM TECHNOLOGIES


MONTREAL, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned subsidiary, BGX E-Health LLC (“BGX”), has received a purchase order to supply Innova Health Care of Saudi Arabia with generic formulations totaling over CAD$1 Million.


The Company has partnered with Montreal-based contract manufacturer BioV Pharma Inc., to fulfill the contract, which will be supplied in two shipments over the next six (6) months The first shipment, which totals approximately CAD$450,000 and is scheduled to be delivered before of the end of this year and the balance of the order is expected to be delivered during the first quarter of 2020.


THE EXPORT MARKET OPPORTUNITY


The Company is currently targeting international export market for its core products and other generic formulations, including Latin America, Asia and the Middle East, the latter being one of major focus in the Company’s near-term revenue growth.


The opportunity in this market is significant and according to Market Data Forecast, the biopharma market is forecasted to grow to $60B by 2025. This growth driven primarily by changing demographics in terms of the aging population, health habits and higher levels of economic spending power. Although over 60% of the overseas market share is held by multinationals, smaller companies like Relevium have an opportunity to play a significant role in both generic and custom formulations.


Aurelio Useche, CEO of Relevium Technologies stated: “Although our core business model is the online business, in particular for North America and the UK, we are identifying exciting new opportunities in the export markets for Relevium outside our traditional online model. This initial contract reflects a significant opportunity and a key growth channel for BGX and its brands abroad.”


About Relevium Technologies


Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

10 days ago

8020 Admin posted a press release Relevium Enters Into LOI to Unlock Value of Wholly Owned Subsidiary BGX E-Health LLC and Announces Conference Call With CEO in RELEVIUM TECHNOLOGIES


MONTREAL, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce On October 25, 2019, the Company received a letter of intent (the “LOI”) to roll its interest in its wholly owned subsidiary BGX e-Health LLC into Newscope Capital Corporation (“Newscope”), a BC based privately held company seeking to become an aggregator in the wellness space, including CBD and hemp space.


Under the preliminary terms of the LOI, Relevium with is expected to receive 20 Million shares of Newscope at $0.50 per share, representing approximately 86% of the resulting issuer. The total proposed transaction value is CAD$10 Million, which includes the business, its assets and liabilities, intellectual property and certain key agreements currently under consideration and review by management.


Newscope intends to complete a listing on the CSE before the second quarter of 2020.


Aurelio Useche, CEO of Relevium Technologies stated: “RLV’s valuation today is not representative of the sum of all its components. We have been working diligently to unlock the embedded value of each of our individual businesses, which will provide shareholders with the true value that each business unit has to offer.” Mr. Useche stated further: “The proposed transaction with Newscope is the first step in further unlocking the value of RLV’s components and we are looking forward to working with them to execute the acquisition strategy, growing sales, expanding product offerings and increasing the company’s global footprint.”


The LOI is subject to customary conditions associated with such a transaction including due diligence as well as internal, external compliance reviews and shareholder approval. Additional information about the board, management and pertinent transaction details including post transaction details will be provided in a subsequent news release.


CONFERENCE CALL WITH CEO


We are delighted to announce a conference call with Aurelio Useche, CEO of Relevium Technologies, to discuss the company’s results for the fiscal year ended June 30, 2019 and to discuss the company’s progress and plans for 2020.


The conference call will take place this Friday November 1, 2019 at 4:00pm (16:00) via our conference portal. You must pre-register to attend this call. Please use this link to register your attendance: https://zoom.us/meeting/register/6d084fc83a0b7f6dd746f627e8486654


About Relevium Technologies


Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

22 days ago

8020 Admin posted a press release Relevium Acquires 100% of Late Stage Processing and Medical Sales Applicant Weedsense in RELEVIUM TECHNOLOGIES


MONTREAL, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly- owned subsidiary, Biocannabix (“BCX”), has executed an Agreement (the “Agreement”) to acquire 100% of the shares of Weedsense Inc. (“Weedsense”), a late stage applicant for a Standard Processing and Medical Sales license under the Cannabis Act, for an aggregate purchase price of $2,000,000 subject to the achievement of certain milestones.


Weedsense is a Montreal- based business that will build a wholesale and distribution facility outside of the downtown core. Weedsense will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and will be distributing cannabis and cannabis-derived products directly to medical patients.


Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”). Excess capacity at the facility may be rented out once fully licensed, and Weedsense can and may act as a secured storage facility or third party logistics (“3PL”) partner for other market participants who seek direct access to the Quebec market who are in need compliant storage or pick/pack solutions.


Weedsense has applied for a Standard Processing and a Medical Sales license under the Cannabis Act through Health Canada and has since received a positive Status Update to build the project. The facility will be built out to EU GMP standards and will seek EU GMP certification in the near future.


Dave Shepard, CEO and Co-Founder of Weedsense Inc. stated: “We began the transactional process with Relevium in May for a direct investment and, through the last few months, both parties concluded that a full acquisition was the most beneficial avenue for generating shareholder value as well as executing on the buildup of the Weedsense facility.”


Sasha Asgary, COO and Co-Founder of Weedsense stated: “The intended purpose of Weedsense is to solve some of the major supply chain issues that are prevalent in the cannabis market today which include getting products to the medical and recreational markets.” Mr. Asgary continued: “With Cannabis 2.0 coming into effect today, the already fragmented upstream will be further complicated by a host of new suppliers of derivative products nationwide. We think that, in collaboration with Relevium, Weedsense will be in a position to offer a superior user experience to all potential customer and client verticals be it on a D2C or B2B basis or as a service provider within the industry.”


Aurelio Useche, CEO of Relevium stated: “The acquisition of Weedsense is an important milestone for Relevium and Biocannabix as the acquisition of this late stage applicant will help us accelerate our path in distributing cannabis products within our home market in Canada.” Mr. Useche further stated: “Once the Weedsense facility receives approval from Health Canada, we will be able to hold inventory and distribute any products regulated under the Cannabis Act most notable of which will be the CannakidsTM products. This will be the beginning of generating significant Canadian revenues under Biocannabix. We are thrilled to have executed this agreement and look forward to working with Dave and Sasha on building out the facility and building up the business.”


Transaction Structure


The aggregate purchase price (the “Purchase Price”) payable by Relevium (the “Purchaser”) to Weedsense (the “Vendor”) is $2,000,000, payable in four performance-based installments.


Upon the execution of the Agreement, Relevium will make an initial payment of $500,000 of the Purchase Price (the “Initial Deposit Amount”) by issuing and delivering an aggregate of 7,142,857 Purchaser Shares.


Subsequent to the Initial Payment, Purchaser will pay the balance of the Purchase Price as follows:



  1. On the day of submission of the Site Video Evidence Package to Health Canada, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Second Deposit Amount”);


  2. On the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Third Deposit Amount”); and


  3. Upon the earlier of (i) the first sale of any cannabis product by the Vendor to any customer, which may include any distributor, wholesaler, retailer or other consumer of cannabis products (the “Date of Commercialization”) and (ii) the first anniversary of the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay the final $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (at the election of the Vendors).


Within 30 days following the first 12 months of operations of Weedsense commencing on the Date of Commercialization, the Purchaser shall cause the Vendor to prepare an accounting of its gross sales during such 12 month period, prepared in accordance with Canadian generally accepted accounting principles applicable to private enterprises (the “Statement of Sales”). Within two Business Days after the preparation of the Statement of Sales, the Purchaser shall deliver the Statement of Sales, and all related supporting and background documentation, to the Vendors. If the gross sales as shown on the Statement of Sales is equal to or greater than $1,250,000.00, the Purchaser shall pay an aggregate of $250,000 in cash.


On the date of the Agreement, the Purchaser shall pay to the Vendor the amount of $10,000 in immediately available funds for the purposes of funding the Vendor’s operating expenses. Commencing in the first month following the date of this Agreement, and continuing through to and including February 2020, the Purchaser shall pay to the Vendor $5,000 per month for the purposes of funding the Vendor’s operating expenses.


By no later than March 1, 2020, the Purchaser shall pay to the Vendor, the amount of $750,000 in immediately available funds for the purposes of funding the build-out of the Facility, including leasehold improvements and other modifications to the Facility, in order for the Vendor to seek to obtain the Cannabis License (the “Facility Build-Out Funds”).


By no later than May 31, 2020, the Vendor shall use its commercially reasonable efforts to submit a Site Video Evidence Package to Health Canada in support of the application for the Cannabis License and thereafter shall use its commercially reasonable efforts to diligently pursue the issuance of the Cannabis License from Health Canada.


The Transaction contemplated in the Agreement will close once the Vendor shall have obtained the Cannabis License from Health Canada and all payments necessary will have been delivered by the Purchaser.


The transaction is subject to regulatory approvals including TSX venture Exchange.


About Weedsense Inc.


Weedsense Inc. is a Montreal (Canada) based business that is seeking to build a wholesale and distribution facility outside of the downtown core.


Weedsense will not be cultivating any cannabis at its facility. The Company will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and distributing directly to medical patients. Patients in the Montreal Metro area may enjoy same day delivery and national clients will enjoy national standard delivery times.


Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”).


Excess capacity at the facility may be rented out. Weedsense can and may act as a secured storage facility or third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market, need compliant storage or pick/pack solutions.


Weedsense has applied for a Standard Processing and a Medical Sales licenses through Health Canada and has received a positive Status Update to build. The facility will be built out to EU GMP standards.


About Relevium Technologies


Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb no photo

C Lee

5 months ago

!
Thumb 8020 media relations

Media Relations

7 months ago

Media Relations posted an update Relevium Technologies presenting in Ste-Therese QC this evening in RELEVIUM TECHNOLOGIES

In front of an attentive audience, Mr. Abbis Hussein, VP of Marketing for Relevium Technologies presents the company’s latest developments in Ste-Therese QC, hosted by MI3 Communications of Montreal



 


 

!

Relevium Technologies

publicPublic Group

Relevium is a publicly traded corporation strategically focused the acquisition of e-retail brands, products and technologies in the health and wellness market. Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Our s...

people9 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
Add Corporate Feed


Relevium Technologies

publicPublicGroup

Relevium is a publicly traded corporation strategically focused the acquisition of e-retail brands, products and tech......

people9 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

3 hours ago

8020 Admin posted a press release Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company in RELEVIUM TECHNOLOGIES

Provides Futher Information on Newscope Transaction


MONTREAL, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract manufacturing company through its wholly owned subsidiary BGX e-Health LLC. The transaction is subject to customary due diligence and the parties have agreed to keep the vendors information confidential until such a time when the definitive agreement is executed. 


The target of the transaction is a Montreal based Biopharma company that manufactures for private label, white label and for its own brands of over the counter health products sold in Canada and the US.


The acquisition of the target represents a strategic vertical integration for BGX E-Health, and it is forecasted to have a material impact on the subsidiary’s revenues and a significant increase in gross margins, while providing at the same time immediate access to lucrative news opportunities. The addition of the target will also allow the company to pursue private label solutions in North America and its laboratories will enable the company to conduct research and development for new products.


Proposed terms of the LOI


Subject to customary due diligence, board and TSX Venture approval, the Company intends to close the transaction within 90 days from the date of the definitive agreement. An initial payment of 150,000$ in shares and 100,000$ in cash will be done at closing, with an earnout (the “Earnout”) bonus of $2,500,000 in shares vesting over a period of three reference years (20/30/50) and based on specific revenue and EBITDA targets. The final terms and conditions of the transaction will be outlined at the execution of a definitive agreement. The preliminary terms of the earnout include:



  • First Year: Vendor will be entitled to 20% or $500,000 upon meting the forecasted targets for revenue and EBITDA for the first reference 12-month period.

  • Second Year: Vendor will be entitled to 30% or $750,000 upon meeting the forecasted targets for revenue and EBITDA for the second reference 12-month period.

  • Third Year: Vendor will be entitled to 50% or $1,250,000 upon meeting the forecasted targets for revenue and EBITDA for the third reference 12-month period.


Aurelio Useche, CEO of Relevium Technologies stated: “The proposed acquisition is not only of strategic importance to BGX, but also it is accretive in terms of vertical integration, revenue growth, gross margins and EBITDA. The proposed acquisition is expected to consolidate the manufacturing of all-natural products of future brand acquisitions, thus establishing in Montreal an important manufacturing foothold.”   


INFORMATION UPDATE ON NEWS RELEASE REGARDING LOI WITH NEWSCOPE


On October 29, 2019 the Company disseminated a news release announcing it had received a letter of intent (the “LOI”) to roll its interest in wholly owned subsidiary BGX e-Health LLC into Newscope Capital Corporation (“Newscope”).


Newscope Capital Corporation is an arms’ length company incorporated under the laws of British Columbia and it is seeking to become an aggregator in the wellness space, including CBD and hemp. The bona fide letter of intent to acquire BGX E-Health LLC, represents the first major transaction for Newscope, which is expected to complete its listing on the CSE during the first quarter of 2020.


As described in the news release dated October 29, 2019, the preliminary terms of the LOI require Relevium Technologies to roll its interest in BGX E-Health LLC into Newscope (the “RTO”) for a total estimated transaction value $10 million, a transaction that is subject to the completion mutual due diligence. Newscope will issue an initial deposit of $500,000 in cash upon completion of the due diligence period and execution of a binding agreement. The total proposed transaction includes the business, its assets and liabilities, intellectual property and certain key agreements currently under consideration and review by management. The arm’s length offer has not been validated by an independent valuation contractor.


The foregoing transactions are subject to regulatory approvals. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


About Relevium Technologies
Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

1 day ago

8020 Admin posted a press release Relevium Technologies Appoints Mark Billings as Chief Financial Officer in RELEVIUM TECHNOLOGIES


MONTREAL, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and Biocannabix Health Corporation effective immediately. Mr. Billings replaces Faycal Salek who has resigned to pursue other opportunities.


Mr. Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business. Mr. Billings has founded and managed companies in the junior resource sector, where he acted as CEO, CFO and board member. Mr. Billings serves on the board of several publicly traded resource companies in Canada and abroad. In addition to his executive career, Mr. Billings has been an investment banker, having raised hundreds of millions of dollars for small-cap companies, including several junior mining companies. 


Aurelio Useche, CEO of  Relevium stated: “Mr. Billings is a veteran in the public markets and brings to our company extensive experience in capital markets, M&A transactions and overall financial acumen, all of which are necessary for the next stage of the development of our business. We look forward to his active participation in the strategic planning process, development and execution of the company’s objectives


Mr. Useche continued: “On behalf of the entire board and management team, we would like to thank Mr. Faycal Salek for his valuable contributions and wish him success in his new endeavors.


About Relevium Technologies
Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The Company has an international ecosystem and footprint that ensures vertical integration from phyto-genetics through clinical validation and eventual commercialization of its products.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

9 days ago

8020 Admin posted a press release Relevium's Subsidiary BGX E-Health Secures One Million Dollar Export Contract for the Middle East in RELEVIUM TECHNOLOGIES


MONTREAL, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned subsidiary, BGX E-Health LLC (“BGX”), has received a purchase order to supply Innova Health Care of Saudi Arabia with generic formulations totaling over CAD$1 Million.


The Company has partnered with Montreal-based contract manufacturer BioV Pharma Inc., to fulfill the contract, which will be supplied in two shipments over the next six (6) months The first shipment, which totals approximately CAD$450,000 and is scheduled to be delivered before of the end of this year and the balance of the order is expected to be delivered during the first quarter of 2020.


THE EXPORT MARKET OPPORTUNITY


The Company is currently targeting international export market for its core products and other generic formulations, including Latin America, Asia and the Middle East, the latter being one of major focus in the Company’s near-term revenue growth.


The opportunity in this market is significant and according to Market Data Forecast, the biopharma market is forecasted to grow to $60B by 2025. This growth driven primarily by changing demographics in terms of the aging population, health habits and higher levels of economic spending power. Although over 60% of the overseas market share is held by multinationals, smaller companies like Relevium have an opportunity to play a significant role in both generic and custom formulations.


Aurelio Useche, CEO of Relevium Technologies stated: “Although our core business model is the online business, in particular for North America and the UK, we are identifying exciting new opportunities in the export markets for Relevium outside our traditional online model. This initial contract reflects a significant opportunity and a key growth channel for BGX and its brands abroad.”


About Relevium Technologies


Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

10 days ago

8020 Admin posted a press release Relevium Enters Into LOI to Unlock Value of Wholly Owned Subsidiary BGX E-Health LLC and Announces Conference Call With CEO in RELEVIUM TECHNOLOGIES


MONTREAL, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce On October 25, 2019, the Company received a letter of intent (the “LOI”) to roll its interest in its wholly owned subsidiary BGX e-Health LLC into Newscope Capital Corporation (“Newscope”), a BC based privately held company seeking to become an aggregator in the wellness space, including CBD and hemp space.


Under the preliminary terms of the LOI, Relevium with is expected to receive 20 Million shares of Newscope at $0.50 per share, representing approximately 86% of the resulting issuer. The total proposed transaction value is CAD$10 Million, which includes the business, its assets and liabilities, intellectual property and certain key agreements currently under consideration and review by management.


Newscope intends to complete a listing on the CSE before the second quarter of 2020.


Aurelio Useche, CEO of Relevium Technologies stated: “RLV’s valuation today is not representative of the sum of all its components. We have been working diligently to unlock the embedded value of each of our individual businesses, which will provide shareholders with the true value that each business unit has to offer.” Mr. Useche stated further: “The proposed transaction with Newscope is the first step in further unlocking the value of RLV’s components and we are looking forward to working with them to execute the acquisition strategy, growing sales, expanding product offerings and increasing the company’s global footprint.”


The LOI is subject to customary conditions associated with such a transaction including due diligence as well as internal, external compliance reviews and shareholder approval. Additional information about the board, management and pertinent transaction details including post transaction details will be provided in a subsequent news release.


CONFERENCE CALL WITH CEO


We are delighted to announce a conference call with Aurelio Useche, CEO of Relevium Technologies, to discuss the company’s results for the fiscal year ended June 30, 2019 and to discuss the company’s progress and plans for 2020.


The conference call will take place this Friday November 1, 2019 at 4:00pm (16:00) via our conference portal. You must pre-register to attend this call. Please use this link to register your attendance: https://zoom.us/meeting/register/6d084fc83a0b7f6dd746f627e8486654


About Relevium Technologies


Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb 8020 monitor 200200 2

8020 Admin

22 days ago

8020 Admin posted a press release Relevium Acquires 100% of Late Stage Processing and Medical Sales Applicant Weedsense in RELEVIUM TECHNOLOGIES


MONTREAL, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly- owned subsidiary, Biocannabix (“BCX”), has executed an Agreement (the “Agreement”) to acquire 100% of the shares of Weedsense Inc. (“Weedsense”), a late stage applicant for a Standard Processing and Medical Sales license under the Cannabis Act, for an aggregate purchase price of $2,000,000 subject to the achievement of certain milestones.


Weedsense is a Montreal- based business that will build a wholesale and distribution facility outside of the downtown core. Weedsense will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and will be distributing cannabis and cannabis-derived products directly to medical patients.


Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”). Excess capacity at the facility may be rented out once fully licensed, and Weedsense can and may act as a secured storage facility or third party logistics (“3PL”) partner for other market participants who seek direct access to the Quebec market who are in need compliant storage or pick/pack solutions.


Weedsense has applied for a Standard Processing and a Medical Sales license under the Cannabis Act through Health Canada and has since received a positive Status Update to build the project. The facility will be built out to EU GMP standards and will seek EU GMP certification in the near future.


Dave Shepard, CEO and Co-Founder of Weedsense Inc. stated: “We began the transactional process with Relevium in May for a direct investment and, through the last few months, both parties concluded that a full acquisition was the most beneficial avenue for generating shareholder value as well as executing on the buildup of the Weedsense facility.”


Sasha Asgary, COO and Co-Founder of Weedsense stated: “The intended purpose of Weedsense is to solve some of the major supply chain issues that are prevalent in the cannabis market today which include getting products to the medical and recreational markets.” Mr. Asgary continued: “With Cannabis 2.0 coming into effect today, the already fragmented upstream will be further complicated by a host of new suppliers of derivative products nationwide. We think that, in collaboration with Relevium, Weedsense will be in a position to offer a superior user experience to all potential customer and client verticals be it on a D2C or B2B basis or as a service provider within the industry.”


Aurelio Useche, CEO of Relevium stated: “The acquisition of Weedsense is an important milestone for Relevium and Biocannabix as the acquisition of this late stage applicant will help us accelerate our path in distributing cannabis products within our home market in Canada.” Mr. Useche further stated: “Once the Weedsense facility receives approval from Health Canada, we will be able to hold inventory and distribute any products regulated under the Cannabis Act most notable of which will be the CannakidsTM products. This will be the beginning of generating significant Canadian revenues under Biocannabix. We are thrilled to have executed this agreement and look forward to working with Dave and Sasha on building out the facility and building up the business.”


Transaction Structure


The aggregate purchase price (the “Purchase Price”) payable by Relevium (the “Purchaser”) to Weedsense (the “Vendor”) is $2,000,000, payable in four performance-based installments.


Upon the execution of the Agreement, Relevium will make an initial payment of $500,000 of the Purchase Price (the “Initial Deposit Amount”) by issuing and delivering an aggregate of 7,142,857 Purchaser Shares.


Subsequent to the Initial Payment, Purchaser will pay the balance of the Purchase Price as follows:



  1. On the day of submission of the Site Video Evidence Package to Health Canada, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Second Deposit Amount”);


  2. On the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Third Deposit Amount”); and


  3. Upon the earlier of (i) the first sale of any cannabis product by the Vendor to any customer, which may include any distributor, wholesaler, retailer or other consumer of cannabis products (the “Date of Commercialization”) and (ii) the first anniversary of the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay the final $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (at the election of the Vendors).


Within 30 days following the first 12 months of operations of Weedsense commencing on the Date of Commercialization, the Purchaser shall cause the Vendor to prepare an accounting of its gross sales during such 12 month period, prepared in accordance with Canadian generally accepted accounting principles applicable to private enterprises (the “Statement of Sales”). Within two Business Days after the preparation of the Statement of Sales, the Purchaser shall deliver the Statement of Sales, and all related supporting and background documentation, to the Vendors. If the gross sales as shown on the Statement of Sales is equal to or greater than $1,250,000.00, the Purchaser shall pay an aggregate of $250,000 in cash.


On the date of the Agreement, the Purchaser shall pay to the Vendor the amount of $10,000 in immediately available funds for the purposes of funding the Vendor’s operating expenses. Commencing in the first month following the date of this Agreement, and continuing through to and including February 2020, the Purchaser shall pay to the Vendor $5,000 per month for the purposes of funding the Vendor’s operating expenses.


By no later than March 1, 2020, the Purchaser shall pay to the Vendor, the amount of $750,000 in immediately available funds for the purposes of funding the build-out of the Facility, including leasehold improvements and other modifications to the Facility, in order for the Vendor to seek to obtain the Cannabis License (the “Facility Build-Out Funds”).


By no later than May 31, 2020, the Vendor shall use its commercially reasonable efforts to submit a Site Video Evidence Package to Health Canada in support of the application for the Cannabis License and thereafter shall use its commercially reasonable efforts to diligently pursue the issuance of the Cannabis License from Health Canada.


The Transaction contemplated in the Agreement will close once the Vendor shall have obtained the Cannabis License from Health Canada and all payments necessary will have been delivered by the Purchaser.


The transaction is subject to regulatory approvals including TSX venture Exchange.


About Weedsense Inc.


Weedsense Inc. is a Montreal (Canada) based business that is seeking to build a wholesale and distribution facility outside of the downtown core.


Weedsense will not be cultivating any cannabis at its facility. The Company will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and distributing directly to medical patients. Patients in the Montreal Metro area may enjoy same day delivery and national clients will enjoy national standard delivery times.


Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”).


Excess capacity at the facility may be rented out. Weedsense can and may act as a secured storage facility or third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market, need compliant storage or pick/pack solutions.


Weedsense has applied for a Standard Processing and a Medical Sales licenses through Health Canada and has received a positive Status Update to build. The facility will be built out to EU GMP standards.


About Relevium Technologies


Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:


BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.


Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Cautionary Note Regarding Forward-Looking Statements


This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", or "would" occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.


Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.


On Behalf of the Board of Directors


RELEVIUM TECHNOLOGIES INC.


Aurelio Useche
President and CEO


For more information about this press release:


Tel: +1.888.528.8687


RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com


Primary Logo


!
Thumb no photo

C Lee

5 months ago

!
Thumb 8020 media relations

Media Relations

7 months ago

Media Relations posted an update Relevium Technologies presenting in Ste-Therese QC this evening in RELEVIUM TECHNOLOGIES

In front of an attentive audience, Mr. Abbis Hussein, VP of Marketing for Relevium Technologies presents the company’s latest developments in Ste-Therese QC, hosted by MI3 Communications of Montreal



 


 

!